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Abstract: This review aimed to provide an overview of the level of maturity of normal tissue complication
probability (NTCP) models for head and neck cancer (HNC) patients. A systematic literature review
was performed to retrieve NTCP models for HNC toxicities. Patient population characteristics, NTCP
model and the predictors, treatment technique and endpoint definition were extracted per article. Models
were then scored based on the TRIPOD (transparent reporting of a multivariable prediction model for
individual prognosis or diagnosis) consensus guidelines to evaluate their generalizability. 335 articles
on photon and proton therapy of HNC were identified and 52 relevant articles were further analyzed.
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4; TRIPOD type 4b: 1), seven articles on hypothyroidism (TRIPOD types 1a-2b: 4; TRIPOD type 3:
1; TRIPOD types 4a: 1 4b:1), four articles on hearing loss and tinnitus (TRIPOD type 1a: 4) and
ten articles on esophagitis (TRIPOD types 1a-2b: 9; TRIPOD type 4a: 1) were included. External
validation studies of HNC NTCP models are scarce. Moreover, the majority of them were validating a
model developed by the same researchers. Only 2 independent external validation studies were found.
There is a strong need to publish external validation studies to get more mature NTCP models applicable
in clinical practice.
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This review aimed to provide an overview of the level of maturity of normal tissue complication proba-
bility (NTCP) models for head and neck cancer (HNC) patients. A systematic literature review was per-
formed to retrieve NTCP models for HNC toxicities. Patient population characteristics, NTCP model and
the predictors, treatment technique and endpoint definition were extracted per article. Models were then
scored based on the TRIPOD (transparent reporting of a multivariable prediction model for individual
prognosis or diagnosis) consensus guidelines to evaluate their generalizability. 335 articles on photon
and proton therapy of HNC were identified and 52 relevant articles were further analyzed. Eighteen arti-
cles on xerostomia and sticky saliva (TRIPOD types 1a-2b: 15; TRIPOD type 3: 1; TRIPOD types 4a: 1 &
4b:1), thirteen articles on dysphagia and tube feeding dependence (TRIPOD types 1a-2b: 7; TRIPOD type
3: 2; TRIPOD types 4a:2 & 4b:2), five articles on oral mucositis (TRIPOD types 1a-2b: 4; TRIPOD type 4b:
1), seven articles on hypothyroidism (TRIPOD types 1a-2b: 4; TRIPOD type 3: 1; TRIPOD types 4a: 1 &
4b:1), four articles on hearing loss and tinnitus (TRIPOD type 1a: 4) and ten articles on esophagitis
(TRIPOD types 1a-2b: 9; TRIPOD type 4a: 1) were included. External validation studies of HNC NTCP mod-
els are scarce. Moreover, the majority of them were validating a model developed by the same research-
ers. Only 2 independent external validation studies were found. There is a strong need to publish external
validation studies to get more mature NTCP models applicable in clinical practice.
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Treatment planning of HNC patients often represents a chal-
lenge. The complexity of HNC treatment planning is due to the
close proximity of organs at risk (OARs) to the planning target vol-
ume (PTV). Multiple guidelines are available in the literature on
delineation of target volumes and OARs, including dose objectives
and constraints [1–3]. If simultaneous sparing of OAR and full PTV
coverage is not possible, physicists and physicians adopt strategies
to either spare healthy tissue at the cost of non-uniform irradiation
of the PTV or irradiate above accepted dose constraints to maintain
target coverage, thereby accepting higher risk of complications.
Several NTCP models have become available in the literature in
the past years for a number of different organs and endpoints.
Potentially, NTCP models can help quantify individual risks to
develop specific toxicities and help physicians and physicists make
an informed decision on a personalized treatment strategy for the
patient. Furthermore, NTCP models could be used as quality indica-
tors, in the frame of semi-automated quality assurance (QA) of
treatment plans.
NTCP models are often developed and internally validated
either by cross-validation, bootstrapping or by randomly splitting
original dataset in test and validation sets [4]. However, validation
in an independent dataset, i.e. evaluation of a model’s performance
beyond its training set, is a crucial step before clinical implementa-
tion of a prediction model in the clinic. Prediction model perfor-
mance measures were traditionally defined as the overall model
performance, discriminative ability and calibration [5]. Overall
model performance is normally indicated by the Brier score, while
discriminative ability is specified by the concordance (c) statistics
or the area under the curve (AUC) of the receiver operating charac-
teristic (ROC) curve, and calibration is explained by the goodness-
of-fit statistics [5]. The Brier score represents the mean squared
error between the actual outcomes, Y, and predictions, p. The Brier
score ranges from 0 for a perfect model to 0.25 for a non-
informative model, assuming that the incidence of the outcome
is 50%. The lower the outcome incidence, the lower the maximum
threshold for a non-informative model [5].
The TRIPOD statement [6] is an annotated checklist of items
created to enhance the quality and transparency of reporting pre-
diction models’ development, validation and performance. Four
items in the TRIPOD statement in particular address the validation
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of models; depending on certain factors a model can be classified
in 4 main types and 3 subtypes. Although not stated in the original
TRIPOD statement, in this article, we split TRIPOD Type 4 studies
into 2 subtypes based on the level of independence from the orig-
inal investigators who developed the model.
– Type 1a defines a model where the predictive performance is
directly evaluated using exactly the same dataset used in model
development.
– Type 1b defines a model where performance is evaluated on a
dataset obtained using resampling techniques on the develop-
ment dataset (internal validation).
– Type 2a defines a model where a dataset is randomly split into
two groups, one used to develop a model and the other to eval-
uate its predictive performance.
– Type 2b applies a more robust technique by non-random split-
ting of data (by location, time etc.).
– Type 3 defines a model developed and evaluated on separate
datasets by the model developers, for example using data from
another institution.
– Type 4a defines a published model which is externally validated
by the same investigators who developed the model.
– Type 4b defines a published model which is externally validated
by independent investigators.
Brodin et al. [7] performed a comprehensive review of NTCP
models in HNC focusing on the validity of QUANTEC dose con-
straints and variation of statistical methodology and reporting of
various NTCP models. In contrast, our review was carried out to
give an overview of the currently published NTCP models and their
respective level of external validation as defined by the TRIPOD
statement [6]. The aim is to provide a perspective of the most gen-
eralized, robust and transportable models currently available and
their potential application both in the clinic and in clinical trials.
Materials and methods
A PubMed search was carried out in March 2019 and updated
through August 2019. Keywords used were combinations of
‘‘NTCP” OR ‘‘normal tissue complication probability” OR ‘‘dose–re
sponse” AND ‘‘radiotherapy” OR ‘‘radiation” OR ‘‘radiation induced”
OR ‘‘complication” for each of the following relevant head and neck
radiation-induced toxicities: ‘‘xerostomia” OR ‘‘dry mouth”; ‘‘sticky
saliva”; ‘‘dysphagia” OR ‘‘swallowing dysfunction”; ‘‘esophagitis”;
‘‘oral mucositis”; ‘‘hypothyroidism”; ‘‘hearing loss” and ‘‘tinnitus”.
The initial search resulted in 213 articles. No limit to the earliest
publication date was applied. The search was extended by refer-
ences cited in the retrieved articles.
The literature search was extended for NTCP models either
developed or validated for proton beam therapy of HNC, using
combinations of ‘‘NTCP” OR ‘‘Normal Tissue Complication Probabil-
ity” AND ‘‘protons”. Overall 122 references were retrieved and
analyzed.
Articles in which a quantitative dose–response model was
developed and/or validated were finally selected for further analy-
sis. Applying our selection criteria, 52 full length articles were
selected from the initial search results and analyzed. The vast
majority (51 articles) described development and/or validation of
models for patients treated with photons. One article reported on
external validation of NTCP models developed for photon therapy
on a patient cohort treated with proton beam therapy [8].
After full text review, data extraction was undertaken. Items for
extraction included: manuscript identifiers (author, title), patient
population characteristics, type of the NTCP model and predictive
variables constituting the model (dosimetric and clinical), radio-
therapy (RT) delivery technique and fractionation schedule,
chemotherapy agent/schedule (if available), endpoint(s) definition
as well as the time point for toxicity measurement and toxicity
scoring system and finally model’s performance measures included
in the paper. The model described in each article was then scored
based on the TRIPOD statement on model development and
validation.
Results
Out of the initial pool of 52 articles, 80% reported exclusively on
model development, i.e. TRIPOD types 1a, 1b, 2a or 2b; 7% reported
on development and validation, i.e. TRIPOD type 3 and 13%
reported on validation of a published model, i.e. TRIPOD types 4a
or 4b. According to our analysis, Blanchard’s article [8] on external
validation of five different toxicities (oral mucositis, dry mouth,
dysphagia, tube feeding dependence and hypothyroidism) from
various source articles as well as external validation of physician-
rated dysphagia by Hansen et al. [9] using patients in the random-
ized controlled DAHANCA19 trial as the validation cohort, were the
only independent external validation articles (Type 4b). All other
type 4 studies were validated on separate datasets by the same
authors who developed the model (Type 4a).
Xerostomia and sticky saliva
Xerostomia and sticky saliva are the most common complica-
tions after RT of HNC. This is reflected in the high number of results
in our search, with a total number of 18 papers referring to 16 ded-
icated models. Ten articles referred to Lyman-Kutcher-Burman
(LKB) type models, while the remaining were multivariate logistic
regression NTCP models. Parotid gland mean dose and the mean
dose to submandibular and sublingual glands were suggested as
the most common predictive factors for xerostomia and sticky sal-
iva incidence respectively.
A summary of the salient characteristics of each model in each
paper is reported in Table 1. Comprehensive information is avail-
able in Supplementary Table S1.
Of 18 studies, 14 models fall in to the TRIPOD type 1a or 1b,
from which only 2 articles reported on overall model performance
either by means of R2 alone [21] or R2 in combination with the
scaled Brier score [24]. Eight of these articles reported discrimina-
tive performance by means of AUC, while calibration was only
measured in one article [14] using calibration slope. Five of these
articles did not report any performance measures.
Only 1 model [19] used non-random splitting of data to develop
a model and evaluate its optimism according to two different time
points, i.e. TRIPOD type 2b. Discriminative power of the model was
the only reported performance measure by AUC.
One article was also dedicated to model development and vali-
dation by the same research group, but using two separate data-
sets, i.e. TRIPOD type 3 [16]. AUC was the single reported
performance measure. This study also provided evidence that the
predictive model developed for head and neck squamous cell car-
cinoma (HNSCC) patients did not perform well among patients
with nasopharyngeal cancer (NPC) and vice versa.
External validation was only performed in 2 articles for 2 logis-
tic regression models, the only TRIPOD type 4 analysis was found
for xerostomia [13,8]. In the study by Beetz et al. [13], overall
model performance, discrimination and calibration were reported
by Brier score, AUC and Hosmer-Lemeshow goodness-of-fit test
respectively. The paper also showed that models developed for
patients treated with 3D-CRT, could not be generalized to patients
treated with IMRT without external validation.
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Finally, Blanchard et al. [8] used AUC to report discrimination
and Hosmer-Lemeshow goodness-of-fit test to report calibration.
In summary, 15 of the aforementioned articles (10 LKB and 5
logistic regression models) have merely developed a predictive
model (TRIPOD types 1a, 1b & 2b), while only one article consid-
ered model development in combination with validation (TRIPOD
type 3). Two articles on xerostomia were scored as TRIPOD types
4. However, only in one case [8] the validation could be scored
as type 4b. This paper, however, evaluated the performance of a
model developed for photon therapy on a dataset of patients trea-
ted with protons.
Dysphagia/swallowing dysfunction and tube feeding dependence
We observed a total of 13 articles (9 distinct models) on dys-
phagia/tube feeding dependence, summarized in Table 2. Nine
out of 13 articles used multivariate logistic regression model, indi-
cating that physician and patient-rated swallowing dysfunction in
HNC patients could not be described by mere dose distribution
parameters. It is apparent from the data provided in Table 2 that
there is a large heterogeneity in dosimetric risk factors among
NTCP models of dysphagia. Nonetheless, pharyngeal constrictor
muscle and supraglottic larynx mean dose were commonly found
to correlate with the risk of dysphagia. Detailed information on
each article can be found in Supplementary Table S2.
Of 13 articles, two studies were assigned TRIPOD type 1a; of
these, one used AUC as the only predictive performance measure
[25], while no model performance was evaluated in the other study
[32]. Four articles were assigned TRIPOD type 1b; 3 of which per-
formed calibration and discrimination evaluation by measures of
AUC, discrimination value or calibration slope while one study only
reported AUC [27]. TRIPOD type 2b was assigned to 1 study [4],
in which by utilizing a multivariate logistic regression model,
the authors assessed model validation temporally, predicting
Table 1
NTCP models of xerostomia.
Endpoint Dosimetric risk factors Clinical risk
factors
Type Performance Measures Reference
Salivary excretion function (scintigraphy) Parotid Gland mean dose None 1a None [10]
Grade 3 + xerostomia (scintigraphy) Parotid gland mean dose None 1a AUC [11]









Patient-rated moderate to severe xerostomia Parotid gland mean dose Age, baseline
xerostomia
score
4a AUC, R2 Nagelkerke, Brier
score, Hosmer-Lemeshow









Patient-rated moderate to severe xerostomia Contralateral parotid gland mean dose Baseline
xerostomia
score
1b AUC, discrimination slope,
calibration slope
[14]
Patient-rated moderate to severe sticky saliva Contralateral submandibular, sublingual
and soft palate glands mean dose
None
Patient-rated moderate to severe sticky saliva Contralateral submandibular, sublingual
and soft palate glands mean dose
None 4b AUC, Hosmer-Lemeshow




Patient-rated moderate to severe xerostomia
(3 months’ time point)
Ipsi/contralateral parotid glands mean dose Age 1b AUC [15]
Patient-rated moderate to severe xerostomia
(12 months’ time point)





Patient-rated moderate to severe xerostomia
(3 months’ time point & HNSCC)
Ipsi/contralateral parotid glands mean dose Age 3 AUC [16]
Patient-rated moderate to severe xerostomia
(3 months’ time point & NPC)
Contralateral parotid gland mean dose Financial
status, Age
Patient-rated moderate to severe xerostomia
(12 months’ time point & HNSCC)
Ipsi/contralateral parotid glands mean dose T-stage
Patient-rated moderate to severe xerostomia
(12 months’ time point & NPC)
Ipsi/contralateral parotid glands mean dose Education
Grade 4 xerostomia (salivary flow) Parotid Gland mean dose None 1a None [17]
Xerostomia (25% salivary flow reduction) Parotid Gland mean dose None 1b AUC [18]
Grade 1 + and grade 2 + xerostomia Parotid Glands mean dose None 2b AUC [19]
Grade 3 xerostomia Parotid Gland mean dose None 1a AUC [20]
Acute (CTCAE v3.0) and chronic (RTOG/EORTC
and LENTSOMA) toxicity
Parotid Gland mean dose None 1a R2 [21]
Stimulated parotid flow Parotid Gland mean dose None 1a None [22]
Stimulated parotid flow Parotid Gland mean dose None 1a None [23]
Patient-rated moderate to severe xerostomia Ipsi/contralateral submandibular parotid





1a Scaled Brier score, R2
Nagelkerke, AUC
[24]
Patient-rated xerostomia Combined contralateral (parotid and
submandibular) glands mean dose
None 1a AUC [25]
Stimulated parotid flow ratio <25% of the
pretreatment flow rate (grade 4 xerostomia
based on RTOG/EORTC)
Parotid Gland mean dose None 1a None [26]
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swallowing dysfunction at later time points. However, there was
no quantitative measures on model performance.
Studies byWopken et al. [35] and Dean et al. [29] were assigned
TRIPOD type 3 in which multivariate logistic regression with
penalized learning method and penalized logistic regression mod-
els were used respectively. High values of AUC in training
(AUC = 0.86) as well as validation cohorts (AUC = 0.82) in model
byWopken et al. [35] were representative of model’s good discrim-
inative ability. Penalized logistic regression model in the article by
Dean et al. [29] was also selected based on its best performance
(assessed by AUC) compared to support vector classification and
random forest classification (RFC) models.
We identified four studies with TRIPOD types 4a & 4b. AUC was
reported in all studies, while overall model performance was
reported in 3 articles out of 4, in one by Nagelkerke’s R2 [34], in
the other by the scaled Brier score [28] and in [9] by Brier score.
Calibration was reported in 3 out of 4 studies by measures of
Hosmer-Lemeshow test [28,8] and visualized by calibration plot
in [9].
In summary, from the 13 articles on dysphagia and tube feeding
dependence, 9 articles were restricted to model development,
either alone (TRIPOD type 1a, 1b or 2b) or in combination with
model validation (TRIPOD type 3), while only 4 articles performed
model validation (TRIPOD types 4a & 4b). The multivariate model
on tube feeding dependence at 6 months post-treatment devel-
oped by Wopken et al. [33] was validated in an external cohort
by the same group [34] (TRIPOD type 4a). External validation of
this model was also performed by a totally independent patient
cohort treated by proton beam therapy by Blanchard et al. [8]. Clin-
ical validation of the multivariate logistic regression model per-
formed by Christianen et al. [28] was also scored as having
TRIPOD type 4a, although it was also an effort to clinically validate
the model previously published by the same group. The multivari-
ate model for physician-rated dysphagia developed by Christianen
et al. [27] was independently validated by Hansen et al. [9]. The
results of the closed testing procedure indicated that an intercept
refitting of the original model creates a better fit for the validation
cohort. To our knowledge, among the aforementioned 4 studies,
the studies by Blanchard et al. [8] and Hansen et al. [9] were the
only TRIPOD type 4b studies.
Oral mucositis
We found 5 articles on oral mucositis. Diverse risk factors were
predicted by different studies. Penalized logistic regression and
Random Forest Classification methods were used by Dean et al.
[36,37] in two publications, while LKB [38] and Logit models [30]
were used as well for modeling of oral mucositis. The summary
of papers could be find in Table 3, and detailed information is in
the Supplementary Table S3.
Table 2
NTCP models of dysphagia/swallowing dysfunction and tube feeding dependence.






muscle & supraglottic larynx mean
dose




Supraglottic larynx, middle and
superior pharyngeal constrictor
muscles mean dose, V60 of the
oesophageal inlet muscle




muscle & supraglottic larynx mean
dose















muscle & supraglottic larynx mean
dose




Grade 2 + swallowing
dysfunction
Pharyngeal muscles mean dose T-stage, bilateral neck irradiation,
weight loss, primary tumor site,
treatment modality
2b None [4]
Grade 3 + and less than
grade 3 dysphagia
V80-V100 of pharyngeal mucosa None 3 AUC [29]




Grade 3 + dysphagia V45 of the cervical esophagus,
Cricopharyngeal muscle mean dose





Grade 2 + dysphagia Total constrictor muscle mean dose Disease site, Age 1a None [32]
Grade 2 + dysphagia superior pharyngeal constrictors
mean dose





parotid, cricopharyngeal muscle mean
dose
Advanced T-stage, moderate weight
loss, severe weight loss, accelerated





















None T-stage, N-stage, moderate weight
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Of 5 articles, 4 models described model development (TRIPOD
type 1a & 1b), while only 1 article validated a previously published
model [8] (TRIPOD type 4b).
Four of the articles reported AUC discrimination measures. Only
1 study with TRIPOID type1b [36] performed all model perfor-
mance measures, i.e. overall model performance was reported by
Brier score, discrimination power by AUC and calibration was pre-
sented by calibration slope and intercept, while the other TRIPOD
1b study [37] only reported AUC as the discriminative power per-
formance. In the article by Bhide et al. [30] (TRIPOD type 1a) the
only performance measure reported was R2, while in the corre-
sponding independent external validation study by Blanchard
et al. [8] on proton therapy patients reported both discrimination
ability and calibration of the model by AUC and Hosmer-
Lemeshow test respectively. AUC was the only reported perfor-
mance measure for TRIPOD 1a study by [38].
Despite the relatively good performance of these models
assessed by cross-validation techniques in the internal dataset,
the predictive power of these models has been rarely validated
on an external dataset to confirm the generalizability of the predic-
tions. To the best of our knowledge, the external validation study
performed by Blanchard et al. [8] was the only study which could
be assigned TRIPOD type 4b.
Hearing loss and tinnitus
One article reported on the incidence of tinnitus after HNC IMRT
[39] and three articles addressed hearing loss are summarized in
Table 4. Detailed information is reported in Supplementary
Table S4. Radiation dose to cochlea is the most reported major pre-
dictive factor of hearing loss. LKB model was used in all four arti-
cles, however in the study by Cheraghi et al. [40] logistic, relative
seriality, Critical volume individual and Critical volume population
models were used as well. LKB and logistic models were used in
the model developed on tinnitus [39].
None of the studies found on hearing loss and tinnitus were val-
idated internally (TRIPOD type 1a). Considering performance mea-
sures of NTCP models on hearing loss: AUC was reported in the
model developed by De Marzi et al. [41] and calibration was
reported for the six models developed by Cheraghi et al. [40], while
no performance measures was used by Mosleh-Shirazi et al [42].
The overall performance, discrimination and calibration of the
LKB and logistic NTCP models on tinnitus [39] were measured
using the scaled Brier score and AUC, Hosmer-Lemeshow tests
and the calibration slope respectively which showed satisfactory
results with similar performance for the two models.
Hypothyroidism
We identified 7 articles (5 models) with a quantitative analysis
of thyroid gland radiation-induced complications, summarized in
Table 5. A detailed description can be found in Supplementary
Table S5.
Multivariate logistic model was used for all articles. Mean dose
to thyroid gland and thyroid volume were the most prominent fac-
tors associated with the risk of hypothyroidism.
Out of 7 studies, 4 models had TRIPOD types 1a or 1b. One study
which was assigned as having TRIPOD type 1a [43], used 2-sample
Kolmogorov-Smirnov goodness-of-fit test to evaluate calibration,
while no other performance measures was performed for discrim-
ination or overall performance. Discrimination was measured by
AUC and discrimination slope by Boomsma et al. [44] (TRIPOD type
1b). In the other TRIPOD type 1b study by Ronjom et al. [46] no
performance measure was performed.
One study developed a biochemical hypothyroidism model and
validated it in a different dataset (TRIPOD type 3) [45]. Discrimina-
tive performance was the only reported performance measure by
AUC in this study.
Two studies were assigned TRIPOD types 4a and 4b. One, type
4b external validation, used a model originally developed for
patients treated with 3D-CRT or IMRT [44] and validated them
for patients treated with intensity modulated proton beam therapy
[8]. Calibration and discrimination were measured by the Hosmer-
Lemeshow test and AUC respectively. The other TRIPOD 4a study
Table 3
NTCP models of oral mucositis.
Endpoint Dosimetric risk factors Clinical risk
factors
Type Performance Measures Reference
Severe (grade 3+) and non-severe (less than
grade 3) mucositis




1b AUC, Brier score, Calibration
slope & intercept
[36]
Severe (grade 3 + ) and non-severe (less than
grade 3) mucositis
V180 & V220 of the oral cavity/
oral mucosa
Age 1b AUC [37]
Grade 3 oral mucositis Mean dose to the oral mucosa None 1a R2 value for goodness of fit [30]
Grade 3 + acute mucositis Same as above Same as above 4b R2, AUC, Hosmer-Lemeshow test [8]: External valida-
tion of [30]
Grade 3 + acute mucositis Mean dose to oral/pharyngeal
mucosa
None 1a AUC [38]
Table 4
NTCP models of hearing loss and tinnitus.
Endpoint Dosimetric risk factors Clinical risk
factors
Type Performance Measures Reference
Grade 2 + tinnitus Mean dose to cochlea None 1a Scaled Brier score, AUC, calibration
slope
[39]
Grade 1–2 ear and pituitary gland late
complications
Mean dose and gEUD with a values 1.2 to
the cochlea
None 1a AUC [41]
Sensorineural hearing loss Mean dose to cochlea None 1a 2-sample Kolmogorov-Smirnov
goodness of fit test
[40]
Conductive hearing loss Mean dose to the middle ear None 1a None [42]
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was carried out by the same group who had previously developed
the model [47], where Pearson’s R2 statistics was used as a mea-
sure of overall model performance.
To summarize, out of 7 articles on hypothyroidism, 4 were ded-
icated to model development (TRIPOD type 1a or 1b), 1 on model
development and validation in the same article (TRIPOD type 3)
and 2 on model validation only (TRIPOD types 4a & 4b).
Esophagitis
A total of 10 articles (9 models) were reviewed for esophagitis,
summarized in Table 6. Details of the articles are provided in Sup-
plementary Table S6.
Quantitative dose–response models of esophagus toxicity are
mainly developed for non-small cell lung cancer (NSCLC) patients.
Mean dose to esophagus and concurrent chemotherapy were rec-
ognized as the most highly reported dosimetric and clinical prog-
nostic factors respectively for esophagitis incidence.
Out of 10 articles, 9 reported on model development only and
were assigned TRIPOD type1a or 1b, six of which, all with TRIPOD
type 1a, did not provide any performance measures. One type 1a
study [57], however, provided discrimination by AUC. Two articles
with TRIPOD type 1b provided some performance measures:
Huang et al. [52] reported discrimination (AUC) and a calibration
plot; Wijsman [50] reported all three measures of model perfor-
mance using Nagelkerke’s R2, calibration plot coupled with
Hosmer-Lemeshow test and AUC. While the model’s external vali-
dation by Dankers et al. [51] only performed discriminative perfor-
mance by AUC.
In sum, from 10 total articles, 9 were dedicated to model devel-
opment only (TRIPOD types 1a & 1b) while only 1 TRIPOD type 4a
study was observed.
Discussion
A comprehensive literature review on NTCP models relevant
to radiation-induced HNC toxicities was performed. Our review
demonstrated scarcity of external validation studies, specifically
by independent investigators. The purpose of a prediction model
is by definition to provide reliable outcome predictions. To this
end, external validation is of high importance, since it is very
probable to develop a model which performs well in the training
dataset but fails when applied to out-sample data. It is an essen-
tial step for generalizability, transportability and causality
appraisal of the predicted models in an independent patient
cohort.
In this study we utilized the TRIPOD statement as a way to
quantitatively analyze the prediction strength of the models. Based
on our analysis, 80% of articles are dedicated to model develop-
ment only, from which only 13% have been externally validated.
Two independent external validation studies were observed; one
of which validated five models developed for photon radiotherapy
on a population of proton therapy patients. The second article was
Table 5
NTCP models of hypothyroidism.
Endpoint Dosimetric risk factors Clinical risk factors Type Performance measures Reference
Grade 1 + hypothyroidism Mean dose to thyroid gland None 1a 2-sample Kolmogorov-Smirnov




Mean dose to thyroid gland Thyroid gland
volume
1b AUC, discrimination slope [44]






















1b Hosmer-Lemeshow test, AUC [48]
*Thyroid stimulating hormone.
Table 6
NTCP models of esophagitis.
Endpoint Dosimetric risk factors Clinical risk factors Type Performance Measures Reference
Grade 2 and grade 3 (acute
esophageal toxicity)
V50 of the esophagus None 1a None [49]
Grade 2 acute esophageal
toxicity
Esophagus mean dose tumor stage, gender,
concurrent chemotherapy
1b AUC, Calibration plot, Hosmer
Lemeshow test, Nagelkerke’s R2
[50]
Grade 2 acute esophageal
toxicity
Same as above Same as above 4a AUC [51]: External vali-
dation of [50]
Grade 2 acute esophagitis Esophagus mean dose Concurrent Chemotherapy 1b AUC, Calibration plot [52]
Grade >2 acute esophagitis Esophagus mean dose None 1a None [53]
Grade 2 >esophagitis Esophagus mean dose None 1a None [54]
Maximal acute esophageal
toxicity at any time point
Esophagus mean dose, V35
of esophagus
Concurrent chemo-RT 1a None [55]
Grade 2 >acute esophagitis V38 of esophagus,
Esophagus mean dose
None 1a None [56]
Patient-rated esophageal
stricture
s value (relative seriality
parameter).
None 1a AUC, Pearson’s v2 test [57]
Grade 3 severe late esophagus
toxicity
Esophagus EUD, V76.7 Gy
to the esophagus
None 1a None [58]
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dedicated to independent external validation of a multivariate
model for physician-rated dysphagia using patients from the
DAHANCA19 trial as the validation cohort. It should be noted that
if the datasets used for external validation are collected by the
same researchers who developed the model, this external valida-
tion is still not considered as fully independent validation. More-
over, it should be noted that even a single external validation
does not label a model as ‘validated’: the more frequently a model
is externally validated and the more diverse are the validation
cohort settings (e.g. patients treated with a different technique,
at a different hospital or a different time point, etc.) the more
assurance can be gained regarding model’s generalizability. We
would like to mention a type of indirect model validation, i.e.,
examination of NTCP curves for different clinically-relevant assess-
ments of a specific toxicity. This type of model validation for late
dysphagia was studied by Eisbruch et al. [59] and demonstrated
that objective assessment of dysphagia, either as Videofluoroscopy
Summary Score or Increase in Aspirations both for pharyngeal con-
strictor mean dose or glottis and supraglottic larynx, led to the
same NTCP. The same result was gained for different patient-
reported outcomes.
During our analysis, we were also concerned about the usage of
performance measures in each article. Based on our analysis, 13%
of the articles reported all performance measures (overall model
performance, calibration & discrimination). For the sake of trans-
parent reporting, it is highly recommended that authors include
performance metrics, specifically discrimination and calibration,
in their final report. Transparent reporting would also make the
process of independent validation more straightforward; because
direct comparison of the discriminative and calibration measures
between validation and training cohorts, and finally the external
validation of the model, becomes feasible.
The lack of external and independent validation of NTCP models
of the head and neck represents also a missed opportunity for the
larger radiation oncology community: validated and accurate pre-
diction models could be incorporated as a tool in the clinic and
help inform decisions and choices made by the planning team,
e.g. on OAR sparing vs PTV coverage. However, several indepen-
dent external validation studies would be a prerequisite to such
developments.
In the context of clinical trials, such NTCP models would also be
extremely useful in quality assurance of patient plans. Unaccept-
able toxicity risk thresholds could be implemented in Radiation
Therapy Quality Assurance (RTQA) guidelines to supplement
QUANTEC- or consensus-defined dose constraints. The feasibility
of such implementation is currently being investigated by our
group at the EORTC by validating some of the cited models using
an independent patient dataset from the EORTC HNCG-ROG 1219
DAHANCA trial. The final validated models could be selected
prospectively as outcome predictors for patients recruited in future
EORTC trials and systematically used as a QA tool.
In order to gain assurance on a model’s generalizability and
clinical usefulness, external validation studies would be highly
welcomed by other independent groups as well, to warrant the
diversity of patient and treatment-related characteristics and to
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